43% of physicians paid through value-based care

Less than half—only 43 percent—of physicians say at least some of their pay comes from value-based care, according to a new survey from national physician search firm The Medicus Firm.

The survey, now in is 15th year running, reflects insight from 2,219 doctors, nurse practitioners and physician assistants across 20 medical specialties from across the country.

The results revealed that fewer than half of doctors were certain that their compensation plan included some component of value-based care, while half reported that 10 percent or less of their total income comes from value-based care.

The findings underscore that the shift from value to volume across the healthcare system still has a long way to go.

"The more things change, the more they stay the same," Jim Stone, president of The Medicus Firm, said of the study. "As the healthcare industry continually evolves, physicians have had to adapt to countless changes throughout their careers, from new technology and clinical developments, to new insurance plans, legislative changes and more. However, despite the ever-changing nature of the industry, some trends seem to consistently ring true over the years." 

Physicians were also asked their preferred type of community and region to live and work. While larger metro areas and suburban communities dominated the responses, experienced were more open to smaller communities.

Among the top most preferred practice settings, 32 percent of physicians said they prefer single-specialty groups and 20 percent preferred hospital employment, a 4 percent increase over last year’s interest in hospital employment, according to the study.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.